Eli Lilly Enters the Indian Market with Trulicity

Summary

In India, Eli Lilly launched an anti-diabetes drug that can be injected once a week.

The Indian diabetes market is huge and it is likely to grow exponentially.

Eli Lilly has recently been rated ‘outperform’.

Just a couple of weeks ago, Eli Lilly (NYSE:LLY) launched its anti-diabetes drug Trulicity (dulaglutide) in India, a country witnessing epic proportions of diabetic patients in its hospitals. Trulicity is a once-a-week non-insulin drug that is recommended for type 2 diabetes. click here to read more.

Would be more interesting if they said something about what it does.